Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.
相关临床试验
21
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
11
52.4%
尚未招募
2
9.5%
招募中
7
33.3%
暂停
1
4.8%
暂无批准数据
- Japanese researchers have isolated 10 natural compounds called onnamides from Okinawan marine sponges, with two showing exceptional activity against Leishmania major parasites. - Onnamide A and 6,7-dihydro-onnamide A demonstrated superior potency and safety compared to current leishmaniasis treatments, while operating through distinct mechanisms that could overcome drug resistance. - The compounds showed strong selectivity for parasites over human cells and may enable shorter treatment durations at lower concentrations. - Research is advancing under Japan's AMED Drug Discovery Booster program, with efforts underway to develop sustainable production methods using symbiotic bacteria.
- Elix and LINC have commercialized the world's first AI drug discovery platform incorporating federated learning models trained on data from 16 pharmaceutical companies, addressing the critical data scarcity challenge in AI drug discovery. - The platform leverages over 1 million compounds and 10 million data points through the kMoL federated learning library, enabling collaborative AI model development while preserving confidential pharmaceutical data. - The initiative emerged from Japan's AMED DAIIA project and includes AI models for on/off-target prediction, ADMET prediction, and molecular generation, with several pharmaceutical companies already adopting the Elix Discovery™ platform. - The commercialization represents a significant milestone in pharmaceutical AI, positioning the platform to become the de-facto standard for AI drug discovery in Japan while contributing to enhanced drug development capabilities globally.
- AvenCell Japan has been awarded up to $40 million in non-dilutive funding from Japan's AMED to support worldwide development of AVC203, a dual-antigen allogeneic CAR-T therapy targeting CD19 and CD20 for B-cell lymphomas. - The company's proprietary allogeneic technology uses multiple gene editing steps to prevent immune rejection while maintaining donor T-cell fitness and potency, addressing key challenges that have limited previous allogeneic CAR-T approaches. - Early clinical data from AvenCell's AVC201 program in relapsed and refractory AML patients demonstrate robust cell expansion and persistence beyond the typical one-month rejection period where other allogeneic candidates have failed. - The funding will enable AvenCell to collaborate with Japanese key opinion leaders and stakeholders to advance what the company describes as a paradigm-shifting therapeutic for patients with high unmet medical needs in lymphomas and leukemias.
- PRD Therapeutics has initiated dosing in the first-ever clinical trial of PRD001, a first-in-class SOAT2-selective inhibitor targeting homozygous familial hypercholesterolemia and metabolic dysfunction-associated fatty liver disease. - The Phase 1 study represents a breakthrough as the first clinical trial of an SOAT2-selective inhibitor, distinguishing it from previous SOAT1/2 dual or SOAT1-selective inhibitor trials. - Preclinical studies in animal models demonstrated that PRD001 effectively lowers blood and liver lipids while suppressing fatty liver and atherosclerosis progression without adverse events. - The oral therapy has potential to become the first effective treatment for HoFH patients who suffer from absent or extremely low LDL receptor activity.
- Rakuten Medical's RM-0256, an anti-PD-L1 antibody conjugated with light-activatable dye IR700, has been selected for funding by Japan's AMED under its orphan drug support program. - The novel photoimmunotherapy demonstrates a triple mechanism of action in preclinical studies, targeting PD-L1-expressing tumor cells while activating anti-tumor immunity and providing checkpoint blockade. - The therapy addresses an urgent medical need for patients with unresectable, advanced, or recurrent malignant epithelial tumors who develop resistance to current treatments. - With approximately 22,000 individuals affected by malignant epithelial tumors annually in Japan, RM-0256 represents a potential breakthrough for multiple solid tumor types including melanoma, breast, and urologic cancers.
- RegCell has partnered with GeneFab to transfer and manufacture its regulatory T cell (Treg) therapy platform for autoimmune diseases, with initial focus on autoimmune hepatitis. - The collaboration leverages GeneFab's 92,000 square foot Alameda facility with seven GMP clean rooms to provide end-to-end CRDMO support for RegCell's epigenetic reprogramming platform. - RegCell recently secured $45.8 million in funding, including $8.5M from seed financing and up to $37.3M from Japan's AMED, as it transitions its headquarters to the US and aims for first-in-human trials in 2025.
- Genezen will provide technology transfer, process development, and cGMP manufacturing of lentiviral vectors for Optieum's OPTF01, a CAR-T therapy targeting glioblastoma. - OPTF01 targets FAP-alpha, which is expressed on both tumor cells and surrounding microenvironment cells, potentially disrupting immunosuppression while attacking malignant cells. - The collaboration aims to address critical unmet needs for glioblastoma patients who currently face limited treatment options and poor prognoses.
